Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioGross MarginInvested CapitalMarket Capitalization

Mainz Biomed N.V (MYNZ) EBITDA Margin: 2022-2023

Historic EBITDA Margin for Mainz Biomed N.V (MYNZ) over the last 2 years, with Dec 2023 value amounting to 2,802.51%.

  • Mainz Biomed N.V's EBITDA Margin rose 714281.00% to 2,802.51% in Q4 2023 from the same period last year, while for Dec 2023 it was 2,992.84%, marking a year-over-year increase of 116921.00%. This contributed to the annual value of 2,433.49% for FY2024, which is 55934.00% down from last year.
  • Per Mainz Biomed N.V's latest filing, its EBITDA Margin stood at 2,802.51% for Q4 2023, which was down 12.50% from 3,202.69% recorded in Q3 2023.
  • In the past 5 years, Mainz Biomed N.V's EBITDA Margin registered a high of 5,715.54% during Q3 2022, and its lowest value of -4,340.30% during Q4 2022.
  • In the last 2 years, Mainz Biomed N.V's EBITDA Margin had a median value of 3,276.77% in 2023 and averaged 2,990.57%.
  • Over the last 5 years, Mainz Biomed N.V's EBITDA Margin had its largest YoY gain of 714,281bps in 2023, and its largest YoY loss of 294,819bps in 2023.
  • Over the past 2 years, Mainz Biomed N.V's EBITDA Margin (Quarterly) stood at -4,340.30% in 2022, then surged by 714,281bps to 2,802.51% in 2023.
  • Its last three reported values are 2,802.51% in Q4 2023, 3,202.69% for Q3 2023, and 3,350.84% during Q2 2023.